Feb 07, 2020
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
Jan 30, 2020
Genedata and the Crohn's & Colitis Foundation Collaborate to Improve Patient Care in Crohn's Disease
Jan 27, 2020
Irritable Bowel Syndrome (IBS) Product Earns Top Spot from TopConsumerReviews.com
Jan 15, 2020
NuMedii, Inc. Announces Pharmaceutical Discovery Collaboration For Ulcerative Colitis
Jan 07, 2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
Dec 26, 2019
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
Dec 04, 2019
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference
Nov 25, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in December
Nov 06, 2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
Oct 31, 2019
Salix Announces Issuance of an Additional XIFAXAN® Patent
Oct 30, 2019
Study Shows Human Milk Oligosaccharides Significantly Improve IBS Symptoms
Oct 25, 2019
Scientists to Create a "Gut Cell Atlas" With Funding from the Helmsley Charitable Trust
Oct 22, 2019
Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
Oct 21, 2019
STELARA® (ustekinumab) Data Demonstrate Long-Term Efficacy and Safety Results in Adults with Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial
Oct 14, 2019
Global Irritable Bowel Syndrome (IBS) Therapeutics Industry
Oct 02, 2019
Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program
Sep 26, 2019
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Sep 11, 2019
Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019
Sep 09, 2019
ExeGi Pharma Probiotics to be Studied in Multiple Sclerosis Patients
Sep 06, 2019
Boston Sarcoidosis Education Conference to Take Place September 14, 2019